GLP1R and metabolic dysfunction-associated steatotic liver disease: Both Sodium–Glucose Cotransporter-2 (SGLT2) inhibitors and GLP-1 agonists have well-established cardioprotective properties, which is particularly relevant given the high cardiovascular risk in patients with CKD and NAFLD [110].